Multiple Myeloma Perspective

 
 
  • Multiple Myeloma: On the Horizon   In "On the Horizon," the Mayo team reports on developments in immunotherapies and emerging techniques that are poised to change the management practices of multiple myeloma, including a discussion of how new insights in myeloma cell biology may ultimately cure this disease.
  • Infection Prophylaxis, Immune Therapies Lead ASH Myeloma Data   Dr S. Vincent Rajkumar discusses the most promising new treatments reported for multiple stages of myeloma at this year's ASH meeting.
  • Multiple Myeloma: Recurrent Dilemma   "Recurrent Dilemma" addresses the management of recurrent myeloma. The Mayo team and their patients comment on the challenges of treating and coping with side effects, and touch on the most difficult decision in this setting: when to stop therapy.
  • Top News From ASH 2017: Slideshow Hot topics include moving to newer oral anticoagulants for cancer patients with VTE, plus practice-changing results in chronic lymphocytic leukemia, multiple myeloma, and Hodgkin's lymphoma.
  • Multiple Myeloma: Relapse Options Rewritten   In "Relapse Options Rewritten," Drs Joseph Mikhael and Keith Stewart provide an overview of the expanded array of new agents--several with overlapping indications--and offer guidance in the selection of therapies for patients with early relapsed disease.
  • Multiple Myeloma: Individualizing Initial Therapy   The Mayo team emphasizes the importance of individualizing initial therapy in multiple myeloma, including the option of offering outpatient stem cell transplantation to select patients.
  • Safety With CAR T-Cell Therapy   Dr Stephan Grupp tells the 'inside story' of issues raised at the recent FDA Oncology Drug Advisory Committee meeting on CAR T-cell therapy.
  • European Hematology Association (EHA) 2017 Congress Read clinically focused news coverage of key developments from EHA 2017.
  • Managing the Unique Challenges of Opioids in Cancer Care Pain management is complex for cancer patients and survivors. Clinicians should expect to see more survivors who need help managing their cancer pain as treatments continue extending survival.
  • Joseph Mikhael: ASCO 2017 Takeaways in Myeloma Myeloma expert Joseph Mikhael discusses the studies at ASCO 2017 that affected his practice.
  • Multiple Myeloma: Taking Risk Into Account   'Taking Risk Into Account' focuses on the use of genetic testing to stratify patients' tumors as being at high, intermediate, or standard risk for progression, which allows clinicians to individualize treatment over the course of a patient's disease.
  • Multiple Myeloma: A Changing Landscape   Leading oncologists from the Mayo Clinic chart the optimal course through the changing therapeutic landscape of early relapsed multiple myeloma.
  • Cellular Immunotherapy for Multiple Myeloma Advancing Rapidly Multiple myeloma may be a singularly promising target for cellular immunotherapies, according to data presented at the most recent ASH annual meeting.
  • Myeloma Data at ASH 2016 Focus on Novel Combinations   The presentations at ASH 2016 for multiple myeloma focused on novel drug combinations in various settings, including newly diagnosed myeloma and refractory disease.
  • No Lack of Enthusiasm for CAR-T Development, Experts Say Medscape Oncology asked a spectrum of researchers in the field to speculate on the implications of Novartis's decision to reintegrate cell therapy into its oncology unit.
  • The Future of Cancer Drugs: RNA Therapies, Bacteria, and Viruses Several new classes of anti-cancer therapies are in development with the hope of becoming the next major advance in oncology.
  • Why Cancer Patients Don't Take Their Medications Despite the consequences, a surprisingly high proportion of cancer patients don't take their medications as prescribed, according to studies.
  • A New Oncology Target: The Heart Delivering the most effective dose of chemotherapy without causing cardiotoxicity is a key goal of the emerging field of cardio-oncology. But are the current predictors of cardiotoxic risk adequate?
  • Sorting Through the Confusion of Biologic Drug Names What's in a name? When it comes to the 'mabs,' 'mibs,' and 'nibs' of biologic drugs, more than you may think.
  • Cancer Moonshot: We Have Liftoff Initial reaction to the Moonshot ranged from cynicism to guarded optimism, but no one denies that momentum is building for this national cancer initiative -- and Big Data are the rocket boosters.